Immune Cells from SR/CR Mice Induce the Regression of Established Tumors in BALB/c and C57BL/6 Mice

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Koch, Janne ^a,b   Hau, Jann ^a   Pravsgaard Christensen, Jan ^a   Elvang Jensen, Henrik ^b   Bagge Hansen, Morten ^c   Rieneck, Klaus ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; CANCER RESISTANCE; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; SOLID TUMOR; TUMOR VOLUME;

ANIMALS; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DISEASE SUSCEPTIBILITY; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; LYMPHOCYTES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS; PEROXIDASE;

EID: 84875318764     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059995     Document Type: Article

References (14)

1. Egorov OS, Liu Y, Sargent EE, Drizlikh GI, Egorov IK, (1991) Screening mouse mutations for resistance to cancer metastasis. Immunogenetics 36: 219-223.
2. Cui Z, Willingham MC, Hicks AM, Alexander-Miller MA, Howard TD, et al. (2003) Spontaneous regression of advanced cancer: Identification of a unique genetically determined, age-independent trait in mice. PNAS 100: 6682-6687.
3. Alfaro G, Lomeli C, Ocadiz R, Ortega V, Barrera R, et al. (1992) Immunologic and genetic characterization of S180, a cell line of murine origin capable of growing in different inbred strains of mice. Veterinary immunology and immunopathology 30: 385-398.
4. Hicks AM, Riedlinger G, Willingham MC, Alexander-Miller MA, Von Kap-Herr C, et al. (2006) Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. PNAS 103: 7753-7758.
5. Koch J, Hau J, Jensen H E, Nielsen C H, Rieneck K, (2012) The cellular cancer resistance of the SR/CR mouse. APMIS 120: 974-987.
6. Koch J, Boschnian A, Hau J, Rieneck K, (2008) Frequency of the cancer-resistant phenotype in the SR/CR mice and the effect of litter seriation. In vivo 22: 565-569.
7. Cobbold SP, Martin G, Waldmann H, (1990) The induction of skin graft tolerance in major histocombatibility complex-mismatched or primed recipients: primed T cells can be tolerized in the periphery with anti-CD4 and anti-CD8 antibodies. Eur J Immunology 20: 2747-2755.
8. Cobbold SP, Jayasuriya A, Nash A, Prospero TD, Waldmann H, (1984) Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature 312: 548-551.
9. Hanahan D, Weinberg RA, (2011) Hallmarks of Cancer: The next Generation. Cell 144: 646-674.
10. Cavallo F, Giovanni CD, Nanni P, Forni G, Lollini P-L, (2011) The immune hallmarks of cancer. Cancer Immunol Immunother. 60: 319-326.
11. Li J, King AV, Stickel SL, Burgin KE, Zhang X, et al. (2009) Whole tumor cell vaccine with irradiated S180 cells as adjuvant. Vaccine 27: 558-564.
12. Fink SL, Cookson BT, (2005) Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic Cells. Infection and Immunity 73: 1907-1916.
13. Hicks AM, Willingham MC, Du W, Pang CS, Old LJ, et al. (2006) Effector mechanisms of the anti-cancer immune responses of macrophages in SR/CR mice. Cancer Immunity 6: 11-20.
14. Riedlinger G, Adams JM, Stehle JR, Blanks MJ, Sanders AM, et al. (2010) The spectrum of resistance in SR/CR mice: the critical role of chemoattraction in the cancer/leukocyte interaction. BMC Cancer 10: 179.